MedPath

Aromatherapy in Alzheimer's disease: a randomised controlled trial in comparison with Aricept

Phase 1
Conditions
This is a trial of Aricept versus placebo versus aromatherapy in people with Alzheimer's disease.
Registration Number
EUCTR2005-003269-17-GB
Lead Sponsor
manchester mental health and social care trust
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
150
Inclusion Criteria

Diagnosis of Alzheimer's disease and agitation
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years)
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Sensitivity to cholinesterase inhibitors.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: To assess the efficacy of Aricept against aromatherapy in people with agitation in Alzheimer's disease.;Secondary Objective: To assess the impact on quality of life of these treatments in people with Alzheimer's disease.;Primary end point(s): Change in measures of agitation.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath